Home

HOME CAREER CONTACT US

CIRG

Home

Last update June 20, 2008

CIRG Paris office has moved to a new location, please note our new address:

CIRG - Biopark - 11, rue Watt 75013 Paris France

CIRG Press Release on FDA approval for the TCH arm used in its BICRG 006 study dated May 29 2008

BETH (TRIO-CIRG 011) Press release on the start up of the study for enrolment) dated May 27 2008

Meet us at ASCO 2008 on the TRIO-CIRG booth (20149) for latest information on TRIO-CIRG new studies in breast, ovarian, gastric cancer settings. International phase II and III studies.
For new TRIO-CIRG studies please click in the Studies Summary on left menu side.
SABCS 2007,
Plenary session Dec 13 Dr Slamon presented: "Role of anthracycline -based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease" [abs. 13].
Slamon D, Mackey J, Robert N, Crown J, Martin M, Eiermann W, Pienkowski T, Bee V, Taupin H, Villalobos, Lindsay MA, Riva A, Hurvitz S, Glaspy J, Pauletti G, Sauter G, Press M, CIRG Edmonton Alberta Canada .
"BCIRG 006: Quality of life of patients treated with docetaxel and trastuzumab-based regimens in node positive and high risk node negative HER2 positive early breast cancer" Poster presented by Dr. Au from the Cross Cancer Institute in Edmonton Alberta (Canada) [Abs. 3064]
Heather-Jane Au, N Robert, W Eiermann, T Pienkowski, J Crown, M Martin, M Pawlicki, A Chan, V Bee and D Slamon.
Breast Cancer International Research Group (BCIRG), Edmonton, AB, Canada.

Satellite Symposium held 26 September 2007, at ECCO-14 Barcelona sponsored by sanofi-aventis:

The Art of Oncology - A decade's contribution and experience of the BCIRG in changing the breast cancer paradigm

_____________________________________

Following the merge of CIRG and TORI late 2005, they are now officially incorporated in a new structure named:

TRIO

Translational Research In Oncology

CIRG and TORI are respectively keeping their activities and names and as such, are divisions of the new group TRIO.

The aim of this new group is to further the objective of bringing rational and innovative therapeutic concepts into the clinical trial setting.

Translate preclinical findings into clinical research
Use translational approaches based on the underlying biology of the disease
Conduct innovative clinical research across all phases of drug development and multiple disease sites

For more details on this new structure please access to the newly website: http://www.trioncology.org

_____________________________________

TORI (founded by Dr Dennis Slamon) is an oncology research network linked to several basic research laboratories which evaluate new therapeutic molecules.
TORI labs uses molecularly characterized models of various human malignancies to study new agents to guide the design of Phase I and Phase II Clinical Studies.
Once leading compounds are ready for larger studies, CIRG and its proven network of committed investigators can perform these larger translational trials.

____________________________________________________________

For information on the CIRG clinical studies recent outcome, click on Studies in the left menu

Return to top of page